Novus Biologicals products are now on bio-techne.com

Recombinant Human Thrombopoietin Protein, CF

Images

 
Recombinant Human Thrombopoietin/Tpo (Catalog # 288-TP/CF) stimulates pro­liferation in the MO7e human megakaryocytic leukemic cell line. The ED50 for this effect is 0.3-3 ng/mL.
1 µg/lane of Recombinant Human Thrombopoietin was resolved with SDS-PAGE under reducing (R) conditions and visualized by silver staining, showing major bands at 43-60 kDa.

Product Details

Summary
Reactivity HuSpecies Glossary
Applications Bioactivity
Format
Carrier-Free

Order Details

View Available Formulations
Novus Biologicals is part of Bio-Techne

Shop this product on bio-techne.com

Recombinant Human Thrombopoietin Protein, CF Summary

Details of Functionality
Measured in a cell proliferation assay using MO7e human megakaryocytic leukemic cells. Avanzi, G. et al. (1988) Br. J. Haematol. 69:359. The ED50 for this effect is 0.3-3 ng/mL.
Source
Spodoptera frugiperda, Sf 21 (baculovirus)-derived human Thrombopoietin/Tpo protein
Ser22-Gly353
Accession #
N-terminal Sequence
Ser22
Protein/Peptide Type
Recombinant Proteins
Gene
THPO
Purity
>97%, by SDS-PAGE with silver staining
Endotoxin Note
<1.0 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

Dilutions
  • Bioactivity
Theoretical MW
35 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
SDS-PAGE
43-60 kDa, reducing conditions
Publications
Read Publications using
288-TP/CF in the following applications:

Packaging, Storage & Formulations

Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -70 °C under sterile conditions after reconstitution.
Buffer
Lyophilized from a 0.2 μm filtered solution in Acetonitrile and TFA.
Purity
>97%, by SDS-PAGE with silver staining
Reconstitution Instructions
Reconstitute at 50-200 µg/mL in sterile 4 mM HCl.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human Thrombopoietin Protein, CF

  • Megakaryocyte colony-stimulating factor
  • Megakaryocyte growth and development factor
  • megakaryocyte stimulating factor
  • MGDF
  • MGDFC-mpl ligand
  • MKCSF
  • MK-CSF
  • ML
  • MPL ligand
  • MPLLG
  • MPLLGMGC163194
  • Myeloproliferative leukemia virus oncogene ligand
  • THCYT1
  • THPO
  • thrombopoietin nirs variant 1
  • Thrombopoietin
  • Tpo
  • TPOMKCSF

Background

Thrombopoietin (Tpo), is a key regulator of megakaryocytopoiesis and thrombopoiesis. It is principally produced in the liver and is bound and internalized by the receptor Tpo R/c‑mpl. Defects in the Tpo‑Tpo R signaling pathway are associated with a variety of platelet disorders (1‑3). The 353 amino acid (aa) human Tpo precursor is cleaved to yield the 332 aa mature protein. Mature human Tpo shares approximately 70% aa sequence homology with mouse and rat Tpo. It is an 80‑85 kDa protein that consists of an N‑terminal domain with homology to Erythropoietin (Epo) and a C‑terminal domain that contains multiple N‑linked and O‑linked glycosylation sites (4, 5). Tissue specific alternate splicing of human Tpo generates multiple isoforms with internal deletions, insertions, and/or C‑terminal substitutions (6). Tpo promotes the differentiation, proliferation, and maturation of MK and their progenitors (4, 5, 7). Several other cytokines can promote these functions as well but only in cooperation with Tpo (8, 9). Notably, IL‑3 independently induces MK development, although its effects are restricted to early in the MK lineage (8, 9). Tpo additionally promotes platelet production, aggregation, ECM adhesion, and activation (10, 13). It is cleaved by platelet‑derived thrombin following Arg191 within the C‑terminal domain and subsequently at other sites upon extended digestion (14). Full length Tpo and shorter forms circulate in the plasma (4, 5). The C‑terminal domain is not required for binding to Tpo R or inducing MK growth and differentiation (5). Aside from its hematopoietic effects, Tpo is expressed in the brain where it promotes the apoptosis of hypoxia‑sensitized neurons and inhibits neuronal differentiation by blocking NGF induced signaling (15, 16).

  1. Deutsch, V.R. and A. Tomer (2006) Br. J. Haematol. 134:453.
  2. Kaushansky, K. (2005) J. Clin. Invest. 115:3339.
  3. Li, J. et al. (1999) Br. J. Haematol. 106:345.
  4. Bartley, T.D. et al. (1994) Cell 77:1117.
  5. de Sauvage, F.J. et al. (1994) Nature 369:533.
  6. Marcucci, R. and M. Romano (2008) Biochim. Biophys. Acta 1782:427.
  7. Kaushansky, K. et al. (1994) Nature 369:568.
  8. Kaushansky, K. et al. (1995) Proc. Natl. Acad. Sci. 92:3234.
  9. Broudy, V.C. et al. (1995), Blood 85:1719.
  10. Lok, S.I. et al. (1994) Nature 369:565.
  11. Chen, J. et al. (1995) Blood 86:4054.
  12. Oda, A. et al. (1996) Blood 87:4664.
  13. Van Os, E. et al. (2003) Br. J. Haematol. 121:482.
  14. Kato, T. et al. (1997) Proc. Natl. Acad. Sci. 94:4669.
  15. Ehrenreich, H. et al. (2005) Proc. Natl. Acad. Sci. 102:862.
  16. Samoylenko, A. et al. (2008) Cell. Signal. 20:154.

Customers Who Viewed This Item Also Viewed...

AF1016
Species: Hu
Applications: Neut, Simple Western, WB
255-SC
Species: Hu
Applications: BA
203-IL
Species: Hu
Applications: BA
M6000B
Species: Mu
Applications: ELISA
AF4117
Species: Rt
Applications: IHC, WB
MEP00B
Species: Mu
Applications: ELISA
NBP2-34294
Species: Hu, Mu, Rt
Applications: Flow, IHC, IHC-P
308-FK
Species: Hu
Applications: BA
D1100
Species: Hu
Applications: ELISA
MAB414
Species: Mu
Applications: ELISA(Cap), ELISA(Det), ELISA(Sta), Neut, WB
7954-GM/CF
Species: Hu
Applications: BA
NBP2-59451
Species: Hu
Applications: ELISA, Flow, ICC/IF, MiAr, WB
MAB414
Species: Mu
Applications: ELISA(Cap), ELISA(Det), ELISA(Sta), Neut, WB
DTM100
Species: Hu
Applications: ELISA
7954-GM/CF
Species: Hu
Applications: BA
NBP3-07388
Species: Hu
Applications: Flow, ICC/IF, IHC, IHC-P
NBP2-59376
Species: Hu, Mu, Rt
Applications: ICC/IF, IHC, IHC-P, IP, WB
H00004598-M02
Species: Hu
Applications: ELISA, IHC, IHC-P, S-ELISA, WB
MAB7616
Species: Hu
Applications: CyTOF-ready, Flow, WB

Publications for Thrombopoietin/THPO (288-TP/CF)(88)

We have publications tested in 8 confirmed species: Human, Mouse, Canine, Primate - Callitrix jacchus (Common Marmoset), Primate - Macaca fascicularis (Crab-eating Monkey or Cynomolgus Macaque), Primate - Macaca mulatta (Rhesus Macaque), Primate - Papio anubis (Olive Baboon), Transgenic Mouse.

We have publications tested in 6 applications: Bioassay, Cell Culture, Differentiation, ELISA (Control), ELISA (Standard), Western Blot.


Filter By Application
Bioassay
(71)
Cell Culture
(13)
Differentiation
(2)
ELISA (Control)
(1)
ELISA (Standard)
(1)
Western Blot
(1)
All Applications
Filter By Species
Human
(71)
Mouse
(6)
Canine
(1)
Primate - Callitrix jacchus (Common Marmoset)
(1)
Primate - Macaca fascicularis (Crab-eating Monkey or Cynomolgus Macaque)
(1)
Primate - Macaca mulatta (Rhesus Macaque)
(4)
Primate - Papio anubis (Olive Baboon)
(1)
Transgenic Mouse
(1)
All Species
Showing Publications 1 - 10 of 88. Show All 88 Publications.
Publications using 288-TP/CF Applications Species
S Li, CS Wang, A Montel-Hag, HC Chen, S Lopez, O Zhou, K Dai, S Tsai, W Satyadi, C Botero, C Wong, D Casero, GM Crooks, CS Seet Strength of CAR signaling determines T�cell versus ILC differentiation from pluripotent stem cells Cell Reports, 2023-03-11;42(3):112241. 2023-03-11 [PMID: 36906850] (Bioassay, Human) Bioassay Human
X Liu, N Sato, T Yabushita, J Li, Y Jia, M Tamura, S Asada, T Fujino, T Fukushima, T Yonezawa, Y Tanaka, T Fukuyama, A Tsuchiya, S Shikata, H Iwamura, C Kinouchi, K Komatsu, S Yamasaki, T Shibata, AT Sasaki, J Schibler, M Wunderlich, E O'Brien, B Mizukawa, JC Mulloy, Y Sugiura, H Takizawa, T Shibata, K Miyake, T Kitamura, S Goyama IMPDH inhibition activates TLR-VCAM1 pathway and suppresses the development of MLL-fusion leukemia Embo Molecular Medicine, 2022-12-01;0(0):e15631. 2022-12-01 [PMID: 36453131] (Cell Culture, Human) Cell Culture Human
YS Michaels, JM Edgar, MC Major, EL Castle, C Zimmerman, T Yin, A Hagner, C Lau, HH Hsu, MI Ibañez-Rio, LJ Durland, DJHF Knapp, PW Zandstra DLL4 and VCAM1 enhance the emergence of T cell-competent hematopoietic progenitors from human pluripotent stem cells Science Advances, 2022-08-24;8(34):eabn5522. 2022-08-24 [PMID: 36001668] (Bioassay, Human) Bioassay Human
J Skokowa, B Hernandez, M Coles, M Ritter, M Nasri, J Haaf, N Aghaallaei, Y Xu, P Mir, AC Krahl, KW Rogers, K Maksymenko, B Bajoghli, K Welte, AN Lupas, P Müller, M ElGamacy A topological refactoring design strategy yields highly stable granulopoietic proteins Nature Communications, 2022-05-26;13(1):2948. 2022-05-26 [PMID: 35618709] (Bioassay, Human) Bioassay Human
Y Hayashi, KC Kawabata, Y Tanaka, Y Uehara, Y Mabuchi, K Murakami, A Nishiyama, S Kiryu, Y Yoshioka, Y Ota, T Sugiyama, K Mikami, M Tamura, T Fukushima, S Asada, R Takeda, Y Kunisaki, T Fukuyama, K Yokoyama, T Uchida, M Hagihara, N Ohno, K Usuki, A Tojo, Y Katayama, S Goyama, F Arai, T Tamura, T Nagasawa, T Ochiya, D Inoue, T Kitamura MDS cells impair osteolineage differentiation of MSCs via extracellular vesicles to suppress normal hematopoiesis Cell Reports, 2022-05-10;39(6):110805. 2022-05-10 [PMID: 35545056] (Bioassay, Human) Bioassay Human
SS Sahoo, VB Pastor, C Goodings, RK Voss, EJ Kozyra, A Szvetnik, P Noellke, M Dworzak, J Starý, F Locatelli, R Masetti, M Schmugge, B De Moerloo, A Catala, K Kállay, D Turkiewicz, H Hasle, J Buechner, K Jahnukaine, M Ussowicz, S Polychrono, OP Smith, O Fabri, S Barzilai, V de Haas, I Baumann, S Schwarz-Fu, European W, MR Niewisch, MG Sauer, B Burkhardt, P Lang, P Bader, R Beier, I Müller, MH Albert, R Meisel, A Schulz, G Cario, PK Panda, J Wehrle, S Hirabayash, M Derecka, R Durruthy-D, G Göhring, A Yoshimi-No, M Ku, D Lebrecht, M Erlacher, C Flotho, B Strahm, CM Niemeyer, MW Wlodarski Clinical evolution, genetic landscape and trajectories of clonal hematopoiesis in SAMD9/SAMD9L syndromes Nature Medicine, 2021-10-07;27(10):1806-1817. 2021-10-07 [PMID: 34621053] (Bioassay, Human) Bioassay Human
K Yamamoto, S Goyama, S Asada, T Fujino, T Yonezawa, N Sato, R Takeda, A Tsuchiya, T Fukuyama, Y Tanaka, A Yokoyama, H Toya, A Kon, Y Nannya, R Onoguchi-M, S Nakagawa, T Hirose, S Ogawa, N Akimitsu, T Kitamura A histone modifier, ASXL1, interacts with NONO and is involved in paraspeckle formation in hematopoietic cells Cell Reports, 2021-08-24;36(8):109576. 2021-08-24 [PMID: 34433054] (Bioassay, Human, Mouse) Bioassay Human, Mouse
H Kato, Y Maezawa, Y Ouchi, N Takayama, M Sone, K Sone, A Takada-Wat, K Tsujimura, M Koshizaka, S Nagasawa, H Saitoh, M Ohtaka, M Nakanishi, H Tahara, A Shimamoto, A Iwama, K Eto, K Yokote Generation of disease-specific and CRISPR/Cas9-mediated gene-corrected iPS cells from a patient with adult progeria Werner syndrome Stem Cell Research, 2021-04-23;53(0):102360. 2021-04-23 [PMID: 34087989] (Cell Culture, Human) Cell Culture Human
GA Newby, JS Yen, KJ Woodard, T Mayuranath, CR Lazzarotto, Y Li, H Sheppard-T, SN Porter, Y Yao, K Mayberry, KA Everette, Y Jang, CJ Podracky, E Thaman, C Lechauve, A Sharma, JM Henderson, MF Richter, KT Zhao, SM Miller, T Wang, LW Koblan, AP McCaffrey, JF Tisdale, TA Kalfa, SM Pruett-Mil, SQ Tsai, MJ Weiss, DR Liu Base editing of haematopoietic stem cells rescues sickle cell disease in mice Nature, 2021-06-02;0(0):. 2021-06-02 [PMID: 34079130] (Bioassay, Human) Bioassay Human
S Borst, CC Nations, JG Klein, G Pavani, JA Maguire, RM Camire, MW Drazer, LA Godley, DL French, M Poncz, P Gadue Study of inherited thrombocytopenia resulting from mutations in ETV6 or RUNX1 using a human pluripotent stem cell model Stem Cell Reports, 2021-05-20;16(6):1458-1467. 2021-05-20 [PMID: 34019812] (Bioassay, Human) Bioassay Human
Show All 88 Publications.

Reviews for Thrombopoietin/THPO (288-TP/CF) (0)

There are no reviews for Thrombopoietin/THPO (288-TP/CF). By submitting a review you will receive an Amazon e-Gift Card or Novus Product Discount.
  • Review with no image -- $10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen
  • Review with an image -- $25/€18/£15/$25 CAD/¥150 Yuan/¥2500 Yen

FAQs for Thrombopoietin/THPO (288-TP/CF) (0)

There are no specific FAQs related to this product. Read our general customer & technical service FAQs.

Additional Thrombopoietin/THPO Products

Blogs on Thrombopoietin/THPO

There are no specific blogs for Thrombopoietin/THPO, but you can read our latest blog posts.
Read our latest blog and use the new citation tool on bio-techne.com

Contact Information

Product PDFs

Calculators

Concentration Calculator

The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.

=
÷

Review this Product

Be the first to review our Recombinant Human Thrombopoietin Protein, CF and receive a gift card or discount.

Bioinformatics

Gene Symbol THPO
Uniprot